- Home
- NKSH vs BMEA Comparison
NKSH vs BMEA Comparison
Compare NKSH & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- BMEA
- Stock Information
- Founded
- NKSH 1891
- BMEA 2017
- Country
- NKSH United States
- BMEA United States
- Employees
- NKSH N/A
- BMEA N/A
- Industry
- NKSH Major Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- BMEA Health Care
- Exchange
- NKSH Nasdaq
- BMEA Nasdaq
- Market Cap
- NKSH 180.8M
- BMEA 145.0M
- IPO Year
- NKSH N/A
- BMEA 2021
- Fundamental
- Price
- NKSH $29.14
- BMEA $3.98
- Analyst Decision
- NKSH Strong Buy
- BMEA Buy
- Analyst Count
- NKSH 1
- BMEA 13
- Target Price
- NKSH $38.00
- BMEA $27.92
- AVG Volume (30 Days)
- NKSH 14.2K
- BMEA 939.5K
- Earning Date
- NKSH 10-24-2024
- BMEA 10-29-2024
- Dividend Yield
- NKSH 5.18%
- BMEA N/A
- EPS Growth
- NKSH N/A
- BMEA N/A
- EPS
- NKSH 1.44
- BMEA N/A
- Revenue
- NKSH $43,450,000.00
- BMEA N/A
- Revenue This Year
- NKSH N/A
- BMEA N/A
- Revenue Next Year
- NKSH $19.72
- BMEA N/A
- P/E Ratio
- NKSH $20.17
- BMEA N/A
- Revenue Growth
- NKSH N/A
- BMEA N/A
- 52 Week Low
- NKSH $26.00
- BMEA $3.61
- 52 Week High
- NKSH $35.00
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- NKSH 51.10
- BMEA 35.19
- Support Level
- NKSH $26.00
- BMEA $3.78
- Resistance Level
- NKSH $29.66
- BMEA $4.29
- Average True Range (ATR)
- NKSH 0.94
- BMEA 0.29
- MACD
- NKSH 0.18
- BMEA 0.14
- Stochastic Oscillator
- NKSH 85.79
- BMEA 49.26
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.